For the patients who use the specialty drugs, the Indian firms’ entry holds the promise of lower costs. Indian drug firms can’t afford to delay their reinvention as their traditional business model is deteriorating, said Prakash Agarwal, an analyst at Axis Capital Ltd who follows the Indian companies. More ambitiousThe Indian firms are growing more ambitious in other areas as well. The companies need to pursue more complex targets as prices fall for basic generic treatments. Success at copying cancer therapies or injectable medicines promises greater profits overseas, and could drive India’s family pharmaceutical businesses for another generation.

Source: Mint June 14, 2016 06:56 UTC